Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial

Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial

Introduction Clinical guidelines recommend non-vitamin K antagonist oral anticoagulants (NOACs) over vitamin K antagonists (VKAs) for stroke prevention in most patients with atrial fibrillation (AF). Frail elderly were under-represented in the landmark NOAC-trials, leaving a knowledge gap on the opt...

Full description

Saved in:
Bibliographic Details
Main Authors: Arno W Hoes, Frans H Rutten, Menno V Huisman, Geert-Jan Geersing, Linda P T Joosten, Sander van Doorn, Melchior C Nierman, Nynke M Wiersma, Huiberdina L Koek, Martin E W Hemels, Kit C Roes, Rutger M van den Bor, Wim F Buding
Format: Article
Language:English
Published: BMJ Publishing Group 2019-12-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/9/12/e032488.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/9/12/e032488.full

Similar Items